Nomura K, Shibui S, Watanabe T
Gan To Kagaku Ryoho. 1982 Jul;9(7):1151-63.
It has been suggested that flow cytometric analysis may offer an ability to select drugs for chemotherapy of malignant neoplasms. For this purpose perturbation of cell cycle travers which induced by several anti-cancer drugs were studied to determine the fundamental factors to evaluate the effectiveness of therapy for individual tumors. From these results, we have made a presumption that for the majority drugs studied, the perturbation of cell cycle travers will be proportional to tumor cell kill. Primary cultured cells from the human brain tumor were used to determine the effectiveness of drugs for its treatment using Factor B (the accumulated cells in SG2M phases after anti-cancer drug treatment as the percentage of cells that was previously in SG2M phases) in comparison with the results (dose-response curves) obtained by glioma cell line. The clinical application was tried using these results. A case with malignant astrocytoma had shown 20.8% for ACNU treatment, however, 85.7% for VCR treatment in maximum range of Factor B on the samples of the removed tumor at the operation (cultured cells). This patient was already treated with radiation, ACNU and other anti-cancer drugs but subsequently failed and revealed constant growth in tumor size. Thereafter patient was treated with VCR according to flow cytometric indication, there was a response, that was the first time after the desperate trials of various drugs. It was only one case, nevertheless, this result illustrates the type of studies for our plan to pursue in order to determine if flow cytometric analysis aids in the brain tumor chemotherapy by individualizing patient's treatment in near future.
有人提出，流式细胞术分析可能有助于为恶性肿瘤的化疗选择药物。为此，研究了几种抗癌药物诱导的细胞周期进程扰动，以确定评估个体肿瘤治疗效果的基本因素。根据这些结果，我们推测，对于大多数所研究的药物，细胞周期进程的扰动将与肿瘤细胞杀伤成正比。用人脑肿瘤的原代培养细胞，与胶质瘤细胞系获得的结果（剂量反应曲线）相比，使用因子B（抗癌药物处理后SG2M期积累的细胞占先前处于SG2M期细胞的百分比）来确定药物治疗的有效性。尝试将这些结果应用于临床。一例恶性星形细胞瘤患者，手术切除肿瘤样本（培养细胞）上，ACNU治疗的因子B最大值为20.8%，而VCR治疗为85.7%。该患者已接受放疗、ACNU和其他抗癌药物治疗，但随后病情恶化，肿瘤大小持续增长。此后，根据流式细胞术的指示，患者接受了VCR治疗，出现了反应，这是在各种药物的绝望试验后的首次反应。虽然这只是一个病例，但这一结果说明了我们计划进行的研究类型，以便确定流式细胞术分析在不久的将来是否能通过个性化患者治疗来辅助脑肿瘤化疗。
